“Achievement of Treat-to-Target Thresholds With Envudeucitinib, a Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Results from STRIDE and OLE”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s650. https://doi.org/10.25251/8xwzce61.